FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789792078> ?p ?o ?g. }

• W2789792078 endingPage "439" @default.
• W2789792078 startingPage "431" @default.
• W2789792078 abstract "OBJECTIVE: To assess efficacy and tolerability of ulipristal acetate, a selective progesterone receptor modulator, for treatment of symptomatic uterine leiomyomas. METHODS: This phase 3, double-blind, placebo-controlled study enrolled premenopausal women (aged 18–50 years) with abnormal uterine bleeding, one or more discrete leiomyomas, and uterine size 20 weeks of gestation or less. Patients were randomized 1:1:1 to 5 mg ulipristal, 10 mg ulipristal, or placebo once daily for 12 weeks followed by 12-week drug-free follow-up. Coprimary endpoints were rate of and time to amenorrhea, defined as no bleeding for the last 35 consecutive days of treatment. Secondary endpoints included rates of amenorrhea from day 11 and change from baseline to endpoint in the Revised Activities subscale of the Uterine Fibroid Symptom and Quality of Life questionnaire, which includes questions pertaining to physical and social activities. Safety assessments included adverse event monitoring and endometrial biopsies. A sample size of 150 was planned to compare separately each dose of ulipristal with placebo. RESULTS: From March 2014 to March 2016, 157 patients were randomized. Demographics were similar across treatment groups. Amenorrhea was achieved by 25 of 53 (47.2% [97.5% CI 31.6–63.2]) and 28 of 48 (58.3% [97.5% CI 41.2–74.1]) patients treated with 5 mg and 10 mg ulipristal, respectively, compared with 1 of 56 (1.8% [97.5% CI 0.0–10.9]) placebo-treated patients (both P <.001). Time to amenorrhea was shorter for both ulipristal doses compared with placebo ( P <.001), and both doses of ulipristal resulted in improved quality of life compared with placebo ( P <.001). Common adverse events (5% or greater in either ulipristal group during treatment) were hypertension, elevated blood creatinine phosphokinase, and hot flushes. Serious adverse events occurred in four patients, but none was considered related to treatment. Endometrial biopsies were benign. CONCLUSION: Ulipristal at 5 mg and 10 mg were well tolerated and superior to placebo in rate of and time to amenorrhea in women with symptomatic uterine leiomyomas. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov number, NCT02147197." @default.
• W2789792078 created "2018-03-29" @default.
• W2789792078 creator A5003343672 @default.
• W2789792078 creator A5006193467 @default.
• W2789792078 creator A5015923975 @default.
• W2789792078 creator A5016148637 @default.
• W2789792078 creator A5052899201 @default.
• W2789792078 creator A5067088712 @default.
• W2789792078 creator A5079180373 @default.
• W2789792078 date "2018-03-01" @default.
• W2789792078 modified "2023-10-17" @default.
• W2789792078 title "Ulipristal Acetate for Treatment of Symptomatic Uterine Leiomyomas" @default.
• W2789792078 cites W1853819257 @default.
• W2789792078 cites W1969018878 @default.
• W2789792078 cites W1979175364 @default.
• W2789792078 cites W1983768667 @default.
• W2789792078 cites W1996100965 @default.
• W2789792078 cites W2001262571 @default.
• W2789792078 cites W2005679540 @default.
• W2789792078 cites W2008487912 @default.
• W2789792078 cites W2021171884 @default.
• W2789792078 cites W2026392453 @default.
• W2789792078 cites W2060920420 @default.
• W2789792078 cites W2071333781 @default.
• W2789792078 cites W2085460220 @default.
• W2789792078 cites W2098707038 @default.
• W2789792078 cites W2106587450 @default.
• W2789792078 cites W2144737614 @default.
• W2789792078 cites W2156957181 @default.
• W2789792078 cites W2157785358 @default.
• W2789792078 cites W2529996311 @default.
• W2789792078 cites W2591950961 @default.
• W2789792078 cites W4210998728 @default.
• W2789792078 doi "https://doi.org/10.1097/aog.0000000000002462" @default.
• W2789792078 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7968372" @default.
• W2789792078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29420395" @default.
• W2789792078 hasPublicationYear "2018" @default.
• W2789792078 type Work @default.
• W2789792078 sameAs 2789792078 @default.
• W2789792078 citedByCount "39" @default.
• W2789792078 countsByYear W27897920782018 @default.
• W2789792078 countsByYear W27897920782019 @default.
• W2789792078 countsByYear W27897920782020 @default.
• W2789792078 countsByYear W27897920782021 @default.
• W2789792078 countsByYear W27897920782022 @default.
• W2789792078 countsByYear W27897920782023 @default.
• W2789792078 crossrefType "journal-article" @default.
• W2789792078 hasAuthorship W2789792078A5003343672 @default.
• W2789792078 hasAuthorship W2789792078A5006193467 @default.
• W2789792078 hasAuthorship W2789792078A5015923975 @default.
• W2789792078 hasAuthorship W2789792078A5016148637 @default.
• W2789792078 hasAuthorship W2789792078A5052899201 @default.
• W2789792078 hasAuthorship W2789792078A5067088712 @default.
• W2789792078 hasAuthorship W2789792078A5079180373 @default.
• W2789792078 hasBestOaLocation W27897920782 @default.
• W2789792078 hasConcept C126322002 @default.
• W2789792078 hasConcept C131872663 @default.
• W2789792078 hasConcept C141071460 @default.
• W2789792078 hasConcept C142724271 @default.
• W2789792078 hasConcept C168563851 @default.
• W2789792078 hasConcept C197934379 @default.
• W2789792078 hasConcept C203092338 @default.
• W2789792078 hasConcept C204787440 @default.
• W2789792078 hasConcept C27081682 @default.
• W2789792078 hasConcept C2777486506 @default.
• W2789792078 hasConcept C2777795800 @default.
• W2789792078 hasConcept C2778058571 @default.
• W2789792078 hasConcept C2778375690 @default.
• W2789792078 hasConcept C2779076696 @default.
• W2789792078 hasConcept C2779234561 @default.
• W2789792078 hasConcept C2908647359 @default.
• W2789792078 hasConcept C29456083 @default.
• W2789792078 hasConcept C2986817661 @default.
• W2789792078 hasConcept C54355233 @default.
• W2789792078 hasConcept C71924100 @default.
• W2789792078 hasConcept C86803240 @default.
• W2789792078 hasConcept C90924648 @default.
• W2789792078 hasConcept C99454951 @default.
• W2789792078 hasConceptScore W2789792078C126322002 @default.
• W2789792078 hasConceptScore W2789792078C131872663 @default.
• W2789792078 hasConceptScore W2789792078C141071460 @default.
• W2789792078 hasConceptScore W2789792078C142724271 @default.
• W2789792078 hasConceptScore W2789792078C168563851 @default.
• W2789792078 hasConceptScore W2789792078C197934379 @default.
• W2789792078 hasConceptScore W2789792078C203092338 @default.
• W2789792078 hasConceptScore W2789792078C204787440 @default.
• W2789792078 hasConceptScore W2789792078C27081682 @default.
• W2789792078 hasConceptScore W2789792078C2777486506 @default.
• W2789792078 hasConceptScore W2789792078C2777795800 @default.
• W2789792078 hasConceptScore W2789792078C2778058571 @default.
• W2789792078 hasConceptScore W2789792078C2778375690 @default.
• W2789792078 hasConceptScore W2789792078C2779076696 @default.
• W2789792078 hasConceptScore W2789792078C2779234561 @default.
• W2789792078 hasConceptScore W2789792078C2908647359 @default.
• W2789792078 hasConceptScore W2789792078C29456083 @default.
• W2789792078 hasConceptScore W2789792078C2986817661 @default.
• W2789792078 hasConceptScore W2789792078C54355233 @default.
• W2789792078 hasConceptScore W2789792078C71924100 @default.

• next